20:04 , Feb 4, 2019 |  BC Extra  |  Company News

Management tracks: PhRMA, Amgen, Apellis

Sanofi (NASDAQ:SNY; Euronext:SAN) CEO Olivier Brandicourt became chairman of PhRMA. Brandicourt was chairman-elect and succeeds Robert Bradway, who is chairman and CEO of Amgen Inc. (NASDAQ:AMGN). PhRMA named Giovanni Caforio chairman-elect. Caforio is chairman and...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:31 , Dec 21, 2018 |  BC Extra  |  Company News

Alexion gains early approval for long-acting PNH therapy

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received FDA approval for Ultomiris ravulizumab-cwvz (ALXN1210), the biotech's long-acting formulation of Soliris eculizumab, to treat paroxysmal nocturnal hemoglobinuria. While the approval came nearly two months ahead of the Feb. 18...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
00:47 , Dec 19, 2018 |  BC Extra  |  Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
18:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
18:48 , Oct 18, 2018 |  BC Extra  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) lost $2.85 (17%) to $13.86 on Thursday after it voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
19:36 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Apellis raises $140.3M in follow-on

Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late on April 18 through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is...